MA29333B1 - Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant - Google Patents

Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant

Info

Publication number
MA29333B1
MA29333B1 MA30220A MA30220A MA29333B1 MA 29333 B1 MA29333 B1 MA 29333B1 MA 30220 A MA30220 A MA 30220A MA 30220 A MA30220 A MA 30220A MA 29333 B1 MA29333 B1 MA 29333B1
Authority
MA
Morocco
Prior art keywords
dosers
pharmaceutical preparations
pressurized aerosols
aerosol pharmaceutical
containing sequestrant
Prior art date
Application number
MA30220A
Other languages
English (en)
Inventor
David Andrew Lewis
Brian John Meakin
Maurizio Delcanale
Fausto Pivetti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36490097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29333(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA29333B1 publication Critical patent/MA29333B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)

Abstract

LA PRÉSENTE INVENTION SE RAPPORTE À UNE PRÉPARATION DE SOLUTION POUR AÉROSOL DESTINÉE À ÊTRE UTILISÉE DANS UN INHALATEUR AÉROSOL, QUI CONTIENT AU MOINS UN INGRÉDIENT ACTIF SÉLECTIONNÉ PARMI LES 20-CÉTOSTÉROÏDES ET LES DÉRIVÉS DE LA QUINOLINONE, UN PROPULSEUR CONTENANT UN HYDROFLUOROALCANE ET UN COSOLVANT, STABILISÉS PAR L'AJOUT D'UNE DOSE SPÉCIFIQUE D'UN AGENT SÉQUESTRANT.
MA30220A 2005-02-25 2007-09-11 Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant MA29333B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05004233 2005-02-25

Publications (1)

Publication Number Publication Date
MA29333B1 true MA29333B1 (fr) 2008-03-03

Family

ID=36490097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30220A MA29333B1 (fr) 2005-02-25 2007-09-11 Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant

Country Status (22)

Country Link
US (1) US8877164B2 (fr)
EP (1) EP1850831B1 (fr)
JP (1) JP5259193B2 (fr)
KR (1) KR101313959B1 (fr)
CN (1) CN101119706B (fr)
AR (2) AR054230A1 (fr)
AU (1) AU2006218177B2 (fr)
BR (1) BRPI0607990A2 (fr)
CA (1) CA2594127C (fr)
EA (1) EA013405B1 (fr)
GE (1) GEP20105040B (fr)
IL (1) IL184449A0 (fr)
MA (1) MA29333B1 (fr)
MX (1) MX2007010396A (fr)
NO (1) NO20074854L (fr)
NZ (1) NZ556376A (fr)
PE (1) PE20061011A1 (fr)
SG (1) SG159550A1 (fr)
TN (1) TNSN07289A1 (fr)
UA (1) UA92732C2 (fr)
WO (1) WO2006089656A2 (fr)
ZA (1) ZA200706870B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200602112A1 (ru) * 2004-05-13 2007-04-27 Кьези Фармачеутичи С. П. А. Изделие для медицинского аэрозоля
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
RU2519653C1 (ru) * 2013-02-27 2014-06-20 Шолекс Девелопмент Гмбх, Аэрозольный препарат на основе ипратропия бромида для лечения заболеваний органов дыхания
US10034866B2 (en) * 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129117T3 (es) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
EP0735884B1 (fr) 1993-12-20 2000-04-26 Minnesota Mining And Manufacturing Company Compositions d'aerosols a base de flunisolide
WO1996040042A2 (fr) * 1995-06-07 1996-12-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compositions steroidiennes stabilisees
BR9609307B1 (pt) * 1995-06-27 2010-03-09 preparação farmacêutica para produção de aerossóis inaláveis isentos de propelentes para administração nos pulmões, bem como aerossol compreendendo a mesma.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
WO2001087203A1 (fr) * 2000-05-17 2001-11-22 Chrysalis Technologies Incorporated Solution de budesonide stabilisee et procede de production
EE05167B1 (et) * 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
ME00077B (fr) * 2002-03-01 2010-06-10 Chiesi Farm Spa Preparation superfine de formoterol
RS50735B (sr) 2002-04-12 2010-08-31 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Medikamenti koji sadrže betamimetik lekove i novi lek antiholinesteraze
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
DE10230769A1 (de) 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression

Also Published As

Publication number Publication date
AR054230A1 (es) 2007-06-13
IL184449A0 (en) 2007-10-31
WO2006089656A2 (fr) 2006-08-31
AR099963A2 (es) 2016-08-31
ZA200706870B (en) 2008-11-26
NO20074854L (no) 2007-09-24
JP5259193B2 (ja) 2013-08-07
HK1116337A1 (en) 2008-12-19
EP1850831A2 (fr) 2007-11-07
AU2006218177B2 (en) 2012-04-12
NZ556376A (en) 2010-01-29
CA2594127A1 (fr) 2006-08-31
EA200701805A1 (ru) 2008-02-28
GEP20105040B (en) 2010-07-12
EA013405B1 (ru) 2010-04-30
PE20061011A1 (es) 2006-12-08
AU2006218177A1 (en) 2006-08-31
KR101313959B1 (ko) 2013-10-02
CN101119706B (zh) 2013-04-17
US20060193785A1 (en) 2006-08-31
WO2006089656A3 (fr) 2006-12-21
US8877164B2 (en) 2014-11-04
MX2007010396A (es) 2007-10-19
CA2594127C (fr) 2013-10-15
UA92732C2 (ru) 2010-12-10
EP1850831B1 (fr) 2015-12-02
KR20070107002A (ko) 2007-11-06
TNSN07289A1 (en) 2008-12-31
JP2008537729A (ja) 2008-09-25
CN101119706A (zh) 2008-02-06
SG159550A1 (en) 2010-03-30
BRPI0607990A2 (pt) 2009-10-27

Similar Documents

Publication Publication Date Title
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
WO2003105800A3 (fr) Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l'administration de principes actifs du cannabis
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
TNSN07425A1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
CY1119188T1 (el) Αντιμικροβιακα συντηρητικα για την επιτευξη φαρμακοτεχνικης μορφης πολλαπλης δοσης χρησιμοποιωντας βητα-κυκλοεξτρινες για υγρες μορφες δοσολογιας
TNSN07423A1 (fr) Composition pharmaceutique comprenant un agent antiparasitaire, et un actif choisi parmi le carveol, le thymol, l'eugenol, le borneol, le carvacrol, l 'alpha-ionone ou le beta-ionone
NO20061925L (no) Farmasoytiske preparater for forebyggelse av overdose eller misbruk
WO2006124047A3 (fr) Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
MA29586B1 (fr) Composes inhibiteurs de la dipeptidylpeptidase-iv, methodes de synthese desdits composes, et preparations pharmaceutiques contenant lesdits composes au titre de principe actif
MA26877A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA27008A1 (fr) Composition parenterale reconstituable contenant un inhibiteur de cox-2
MA61691A1 (fr) Administration orale de conjugues antisiens ciblant pcsk9
CY1112637T1 (el) Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης
MA29969B1 (fr) Formulations de quinolinones
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
DK1359939T3 (da) Sammensætning og fremgangsmåde til potensering af lægemidler
WO2005117895A8 (fr) Compositions contenant de la meloxicame